Karen Buck, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 168 N Caseville Rd, Pigeon, MI 48755 Phone: 989-453-2141 Fax: 989-453-4450 |
Mr. Trevor Samuel Mattarella, FNP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 168 N Caseville Rd, Pigeon, MI 48755 Phone: 989-453-2141 Fax: 989-453-2559 |
Lois Booms, F.N.P. Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 168 N Caseville Rd, Pigeon, MI 48755 Phone: 989-453-2141 Fax: 989-453-4450 |
Melissa Lynn Reichelt, FNP-C Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 170 N Caseville Rd, Pigeon, MI 48755 Phone: 989-453-7301 Fax: 989-453-7306 |
Kristie A Smith, NP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 170 N Caseville Rd, Pigeon, MI 48755 Phone: 989-635-4043 |
Ms. Sheena Lynn Damm, FNP-BC Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 168 N Caseville Rd, Pigeon, MI 48755 Phone: 989-453-3223 |
News Archive
AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
The nation's employers can expect medical costs to increase by 9 percent in 2011, a decrease of 0.5 percent from the 2010 growth rate, according to the annual Behind the Numbers report published today by the PricewaterhouseCoopers LLP Health Research Institute. For the first time, the majority of the American workforce is expected to have a health insurance deductible of $400 or more, as more employers return to "indemnity style" cost-sharing by raising out-of-pocket limits, replacing co-pays with co-insurance and adding high-deductible health plans.
An international research team has found a way to improve the anti-cancer effect of a new medicine class called 'Smac mimetics'.
Scientists have identified a key molecule responsible for triggering the chemical processes in our brain linked to our formation of memories. The findings, published in the journal Frontiers in Neural Circuits, reveal a new target for therapeutic interventions to reverse the devastating effects of memory loss.
Boston Scientific Corporation today announced the completion of a public offering of $2 billion aggregate principal amount of its senior notes under the Company's shelf registration statement.
› Verified 3 days ago